scholarly journals Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study

2016 ◽  
Vol 29 (1) ◽  
pp. 36-45 ◽  
Author(s):  
Renata Conforti ◽  
Mario de Cristofaro ◽  
Adriana Cristofano ◽  
Barbara Brogna ◽  
Angela Sardaro ◽  
...  
2002 ◽  
Vol 12 (5) ◽  
pp. 476-483 ◽  
Author(s):  
Alfonso Di Costanzo ◽  
Francesco Di Salle ◽  
Lucio Santoro ◽  
Vincenzo Bonavita ◽  
Gioacchino Tedeschi

2021 ◽  
Vol 8 (1) ◽  
pp. 137-149
Author(s):  
Isabelle Lessard ◽  
Sébastien Gaboury ◽  
Cynthia Gagnon ◽  
Kévin Bouchard ◽  
Kévin Chapron ◽  
...  

Background: Muscle weakness is a cardinal sign of myotonic dystrophy type 1, causing important functional mobility limitations and increasing the risk of falling. As a non-pharmacological, accessible and safe treatment for this population, strength training is an intervention of choice. Objective: To document the effects and acceptability of an individualized semi-supervised home-based exercise program on functional mobility, balance and lower limb strength, and to determine if an assistive training device has a significant impact on outcomes. Methods: This study used a pre-post test design and men with the adult form of DM1 were randomly assigned to the control or device group. The training program was performed three times a week for 10 weeks and included three exercises (sit-to-stand, squat, and alternated lunges). Outcome measures included maximal isometric muscle strength, 10-Meter Walk Test, Mini-BESTest, 30-Second Chair Stand Test and 6-minute walk test. Results: No outcome measures showed a significant difference, except for the strength of the knee flexors muscle group between the two assessments. All participants improved beyond the standard error of measurement in at least two outcome measures. The program and the device were well accepted and all participants reported many perceived improvements at the end of the program. Conclusions: Our results provide encouraging data on the effects and acceptability of a home-based training program for men with the adult form of DM1. These programs would reduce the financial burden on the health system while improving the clinical services offered to this population.


2016 ◽  
Vol 30 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Arsida Bajrami ◽  
Filiz Azman ◽  
Vildan Yayla ◽  
Sultan Cagirici ◽  
Cahit Keskinkiliç ◽  
...  

Myotonic dystrophy type 1 (DM1) is a progressive multisystemic disease with common cognitive deficits and potential brain involvement in addition to the cardinal muscular and systemic symptoms. Impaired mental function associated with nonspecific pathological findings such as white-matter hyperintense lesions (WMHLs), ventricular enlargement and brain atrophy on brain MRI have been previously reported in DM1 patients. While some studies showed correlation of brain morphological changes with neuropsychological and clinical parameters including CTG repeat sizes and disease severity scales in DM1, others failed. The goal of this study was to retrospectively investigate cranial MR abnormalities, predominantly WMHLs, and their effects on clinical and cognitive deficits in a small, phenotypically or genotypically well-characterized cohort of DM1 patients.


2014 ◽  
Vol 72 (11) ◽  
pp. 895-895
Author(s):  
Leonardo Ferreira Caixeta ◽  
Giane Souza Reis ◽  
Ana Caroline Marques Vilela

2019 ◽  
Vol 13 (1) ◽  
Author(s):  
Sarah C. Sasson ◽  
Alastair Corbett ◽  
Andrew J. McLachlan ◽  
R. Chen ◽  
S. A. Adelstein ◽  
...  

Abstract Background Myotonic dystrophy type 1 is an autosomal dominant disorder characterized by muscle weakness, myotonia, cataracts, and cardiac conduction defects; it is associated with expansions of cytosine-thymine-guanine repeats in the myotonic dystrophy protein kinase. Hypogammaglobulinemia is a lesser known association of myotonic dystrophy type 1 and the underlying pathogenesis of immunoglobulin G depletion remains unclear. Case presentation Here we report a kindred of two members (a 62-year-old white woman and a 30-year-old white man; mother and son) with myotonic dystrophy type 1-associated hypogammaglobulinemia associated with altered intravenous immunoglobulin elimination kinetics and reduced half-life. There was no history of systemic immunosuppression or renal or gastrointestinal protein loss in either patient, and no underlying case for a secondary immunodeficiency could be found. One patient required fortnightly intravenous immunoglobulin to maintain adequate trough immunoglobulin G levels. Conclusions Ongoing study of myotonic dystrophy type 1-associated hypogammaglobulinemia using contemporary tools of genomic medicine may help to further delineate the pathogenesis of this entity.


2006 ◽  
Vol 253 (11) ◽  
pp. 1471-1477 ◽  
Author(s):  
Antonio Giorgio ◽  
Maria T. Dotti ◽  
Marco Battaglini ◽  
Silvia Marino ◽  
Marzia Mortilla ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document